E
BIOR

Ergoteles’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Ergoteles’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-102
Closed -$53K – 1753
2021
Q4 		$53K Buy
+102
New +$73.2K ﹤0.01% 1179
2021
Q3 		– Sell
-327
Closed -$292K – 1824
2021
Q2 		$292K Buy
+327
New +$250K 0.01% 1083

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ergoteles's BIOR Position: Q1 2022 in Review

Ergoteles sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2022, closing a stake of 102 shares — an estimated $53K sold.

Ergoteles first reported a position in BIOR in Q2 2021 and held it in 2 quarters. The position peaked at $292K in Q2 2021. 51 funds tracked by Wall St. Rank hold BIOR as of Q1 2022.

  • Ergoteles reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 102 Biora Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $53K.
  • Ergoteles first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Biora Therapeutics, Inc. Common Stock position peaked at $292K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.